<code id='478A871B2F'></code><style id='478A871B2F'></style>
    • <acronym id='478A871B2F'></acronym>
      <center id='478A871B2F'><center id='478A871B2F'><tfoot id='478A871B2F'></tfoot></center><abbr id='478A871B2F'><dir id='478A871B2F'><tfoot id='478A871B2F'></tfoot><noframes id='478A871B2F'>

    • <optgroup id='478A871B2F'><strike id='478A871B2F'><sup id='478A871B2F'></sup></strike><code id='478A871B2F'></code></optgroup>
        1. <b id='478A871B2F'><label id='478A871B2F'><select id='478A871B2F'><dt id='478A871B2F'><span id='478A871B2F'></span></dt></select></label></b><u id='478A871B2F'></u>
          <i id='478A871B2F'><strike id='478A871B2F'><tt id='478A871B2F'><pre id='478A871B2F'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:focus    Page View:3
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In